Lonza, Teva to Form Biosimilars JV; Lonza Starts Up Plant in China

Lonza and Teva Pharmaceutical Industries (Petah Tikva, Israel) say they have agreed to establish a joint venture to develop, manufacture, and market a portfolio of biosimilars. The jv is expected to start up this quarter, pending regulatory approval. Financial details of the deal were not disclosed. Yanai: Biosimilars to drive growth. The companies say they will focus on efficacious, and safe generic equivalents of certain biologic pharmaceuticals, but that they will explore other possibilities in biosimilars beyond the scope of the jv. “We had identified...

This information is only available to Chemical Week subscribers.

Forgot your user ID or password?
Click here to have it sent to you.

Email Address First Name Last Name

Not an IHS Chemical Week 24/7 member yet? Here's why you should be: Searchable online archive access of the last 2 years of Chemical Week. Print or digital magazine subscription Price and market change alerts Economic data and statistics Buyers' Guides Webcasts | whitepapers